News >

Yu Previews Future of Castration-Naive Prostate Cancer

Caroline Seymour
Published: Monday, Jan 14, 2019

Evan Ya-Wen Yu, MD

Evan Ya-Wen Yu, MD

The CHAARTED, STAMPEDE, and LATITUDE trials have manifested in a dramatic clinical benefit for patients with metastatic castration-naïve prostate cancer, explained Evan Y. Yu, MD, enabling physicians to turn their attention toward those with oligometastatic disease, earlier detection, and the potential for metastatic therapy.

State of the Science Summit™ on Genitourinary Cancers, Yu, a professor in the Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discussed the available options for patients with metastatic castration-naïve prostate cancer.

OncLive: What are the current therapies used in patients with metastatic castration-naïve prostate cancer?

Yu: Metastatic castration-naïve prostate cancer is a disease state we're seeing more and more of as time goes on, partially because there's less prostate-specific antigen (PSA) screening. As a result of that, we're seeing patients with an unmet need. Recently, there have been quite a bit of exciting data looking at adding therapies to standard ADT. We've seen that docetaxel has led to a dramatic survival benefit when added to ADT in both the CHAARTED and STAMPEDE trials. When added to ADT, abiraterone with prednisone also [results in] a dramatic survival benefit, as seen in LATITUDE and in an arm in STAMPEDE.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication